Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.84 USD
Change Today -0.04 / -0.68%
Volume 200.6K
CORT On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

corcept therapeutics inc (CORT) Snapshot

Open
$5.88
Previous Close
$5.88
Day High
$5.93
Day Low
$5.74
52 Week High
04/9/15 - $6.65
52 Week Low
05/27/14 - $1.87
Market Cap
629.3M
Average Volume 10 Days
292.7K
EPS TTM
$-0.22
Shares Outstanding
107.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORCEPT THERAPEUTICS INC (CORT)

corcept therapeutics inc (CORT) Related Bloomberg News

View More Bloomberg News

corcept therapeutics inc (CORT) Related Businessweek News

No Related Businessweek News Found

corcept therapeutics inc (CORT) Details

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

50 Employees
Last Reported Date: 03/13/15
Founded in 1998

corcept therapeutics inc (CORT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $571.3K
Chief Financial Officer and Secretary
Total Annual Compensation: $350.9K
Senior Vice President of Oncology
Total Annual Compensation: $397.4K
Chief Accounting Officer, Vice President and ...
Total Annual Compensation: $251.8K
Compensation as of Fiscal Year 2014.

corcept therapeutics inc (CORT) Key Developments

Corcept Therapeutics Incorporated Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Corcept Therapeutics Incorporated announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net revenues of $10,102,000 against $4,405,000 a year ago. Loss from operations was $4,030,000 against $12,859,000 a year ago. Net loss was $4,830,000 against $13,390,000 a year ago. Basic and diluted loss per share was $0.05 against $0.14 a year ago. Non-GAAP net loss was $2,659,000 against $11,508,000 a year ago. Non-GAAP basic and diluted net loss per share was $0.03 against $0.11 a year ago.

Corcept Therapeutics Incorporated to Report Q1, 2015 Results on May 07, 2015

Corcept Therapeutics Incorporated announced that they will report Q1, 2015 results on May 07, 2015

Corcept Therapeutics Incorporated, Q1 2015 Earnings Call, May 07, 2015

Corcept Therapeutics Incorporated, Q1 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORT:US $5.84 USD -0.04

CORT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.98.10 CHF +0.05
View Industry Companies
 

Industry Analysis

CORT

Industry Average

Valuation CORT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.5x
Price/Book 59.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORCEPT THERAPEUTICS INC, please visit www.corcept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.